Bernstein initiated coverage of Intellia Therapeutics with an Outperform rating and $54 price target. The firm calls Intellia its top pick in gene editing. Intellia has a strong lead over the field with its in vivo gene editing platform, which is already clinically validated in the liver in ATTR amyloidosis and hereditary angioedema, the analyst tells investors in a research note. The firm believes NTLA-2001’s superior biomarker reduction will translate into superior clinical outcomes versus silencers.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NTLA:
- Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema
- Intellia Therapeutics upgraded to Outperform from Market Perform at BMO Capital
- “Strong Buy” Intellia Therapeutics Stock (NASDAQ:NTLA) Still Requires Prudence
- Intellia Therapeutics announces FDA clearance of IND for NTLA-2002
- Intellia Therapeutics price target lowered to $111 from $129 at Chardan